Clinical and pharmacokinetic observations with Madopar HBS in hospitalized patients with Parkinson's disease and motor fluctuations.
The efficacy of a novel oral sustained-release preparation of L-dopa (Madopar HBS) was compared to that of previous standard L-dopa treatment in 10 patients with idiopathic Parkinson's disease and severe fluctuations in motor performance in an open inpatient trial. Clinical assessment included evaluation of self-scoring 'on-off' diaries kept by the patients throughout the study. It revealed a reduction of end-of-dose deterioration and, to a lesser degree, of random 'on-off' swings in 6 cases. Doses of Madopar HBS required for an optimal response averaged the 1.6-fold of previous conventional L-dopa. Plasma levels of L-dopa were more stable with Madopar HBS compared to standard L-dopa treatment in 4 of 5 patients.
Poewe
W H
WH
Department of Neurology, Middlesex Hospital, London, UK.
Lees
A J
AJ
Stern
G M
GM
D001545:Benserazide / Q000008:administration & dosage / Q000493:pharmacokinetics / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D003692:Delayed-Action Preparations; D004305:Dose-Response Relationship, Drug; D004338:Drug Combinations / Q000493:pharmacokinetics / Q000627:therapeutic use; D005260:Female; D006760:Hospitalization; D006801:Humans; D006834:Hydrazines / Q000627:therapeutic use*; D007980:Levodopa / Q000097:blood / Q000493:pharmacokinetics / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D009069:Movement Disorders / Q000188:drug therapy* / Q000209:etiology; D010300:Parkinson Disease / Q000150:complications / Q000188:drug therapy* / Q000503:physiopathology
D003692:Delayed-Action Preparations; D004338:Drug Combinations; D006834:Hydrazines; C005177:benserazide, levodopa drug combination; D007980:Levodopa; D001545:Benserazide